Lv1
100 积分 2024-07-15 加入
Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane
15小时前
待确认
Discovery of an Orally Bioavailable Gonadotropin-Releasing Hormone Receptor Antagonist
1个月前
已完结
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment
1个月前
已完结
Elagolix Pharmacokinetic Profiles in Women With Renal or Hepatic Impairment
1个月前
已完结
Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics
1个月前
已完结
Impact of SLCO1B1 Gene Polymorphisms on Vadadustat Pharmacokinetics
1个月前
已完结
Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I
1个月前
已完结
Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I
1个月前
已关闭
Evaluation of OATP1B inhibitory potential using an endogenous biomarker coproporphyrin-I in new drug applications: Case reports submitted by 2024
1个月前
已完结
Risk of haemorrhagic strokes in patients with psychiatric disorders: A systematic review and meta-analysis
6个月前
已完结
皖公网安备34019202002308
